| Net revenues | 44.07M |
| Cost of revenues | -47.62M |
| Gross profit | -3.55M |
| Operating expenses: | |
| Research and development expenses | -1.34M |
| Sales and marketing expenses | -1.91M |
| General and administrative expenses | -4.62M |
| Impairment charge | -11.4M |
| Total operating expenses | -16.07M |
| Operating loss | -19.63M |
| Finance costs, net | -1.71M |
| Government grant income | 85.21K |
| Other (expense) / income | 47.56K |
| Loss before income taxes | -16.63M |
| Income tax benefits | -5.99M |
| Net loss | -22.63M |
| Other comprehensive income | |
| - Foreign currency translation adjustment | 424.18K |
| Comprehensive loss | -22.21M |
| Net loss per share: | |
| - Basic EPS | -1.79 |
| - Diluted EPS | -1.79 |
| Weighted average number of shares of common stock: | |
| - Basic | 12.62M |
| - Diluted | 12.62M |